Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Total Current Liabilities data on record, last reported at $205.2 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 29.07% year-over-year to $205.2 million; the TTM value through Sep 2025 reached $205.2 million, up 29.07%, while the annual FY2024 figure was $173.8 million, 22.91% down from the prior year.
  • Total Current Liabilities reached $205.2 million in Q3 2025 per AMPH's latest filing, up from $176.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $258.0 million in Q3 2023 and bottomed at $94.9 million in Q4 2022.
  • Average Total Current Liabilities over 5 years is $158.7 million, with a median of $137.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 152.43% in 2023, then plummeted 45.49% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $103.8 million in 2021, then decreased by 8.62% to $94.9 million in 2022, then surged by 137.62% to $225.4 million in 2023, then fell by 22.91% to $173.8 million in 2024, then grew by 18.11% to $205.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $205.2 million in Q3 2025, $176.4 million in Q2 2025, and $199.1 million in Q1 2025.